NR4A1 and breast carcinoma: For patients with hormone receptor-positive, HER2-negative (HR+/HER2−) advanced breast cancer, the combination of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) with endocrine therapies has revolutionized treatment.